Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma

Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line immunochemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Borgerding, Andrea, Hasenkamp, Justin, Glaß, Bertram, Wulf, Gerald, Trümper, Lorenz
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808532/
https://www.ncbi.nlm.nih.gov/pubmed/19727725
http://dx.doi.org/10.1007/s00277-009-0820-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808532/
https://www.ncbi.nlm.nih.gov/pubmed/19727725
http://dx.doi.org/10.1007/s00277-009-0820-9

Ejemplares similares